Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) Net Margin (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Net Margin for 7 consecutive years, with 1338.75% as the latest value for Q2 2025.

  • On a quarterly basis, Net Margin changed N/A to 1338.75% in Q2 2025 year-over-year; TTM through Dec 2025 was 7509.39%, a 817559.0% decrease, with the full-year FY2025 number at 4416.22%, down 680354.0% from a year prior.
  • Net Margin was 1338.75% for Q2 2025 at Outlook Therapeutics, down from 679.6% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 1338.75% in Q2 2025 to a low of 1338.75% in Q2 2025.